Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Lymphoma, Follicular 67Lymphoma, Large B-Cell, Diffuse 66Lymphoma, Non-Hodgkin 59Leukemia, Lymphocytic, Chronic, B-Cell 49Lymphoma 48Lymphoma, Mantle-Cell 28Lymphoma, B-Cell, Marginal Zone 23Recurrence 16Lymphoma, B-Cell 14Burkitt Lymphoma 11Neoplasms 7Leukemia 6Lymphoma, Large-Cell, Immunoblastic 5Lymphoma, Large-Cell, Anaplastic 5Waldenstrom Macroglobulinemia 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Myasthenia Gravis 3Hematologic Diseases 3Lymphoproliferative Disorders 2Lymphatic Diseases 2Immunoblastic Lymphadenopathy 2Hodgkin Disease 2Arthritis, Rheumatoid 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Opsoclonus-Myoclonus Syndrome 1Neuroblastoma 1Neoplasms by Histologic Type 1Myelodysplastic Syndromes 1Limb-girdle muscular dystrophy, type 2C 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 1Rituximab 1Magnetic Resonance Spectroscopy 1Hyaluronoglucosaminidase 1CT-P10 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Classic Follicular Lymphoma × Rituximab × Clear all
NCT06337318 2026-05-29

Comparing Rituximab and Mosunetuzumab Drug Treatments for People With Low Tumor Burden Follicular Lymphoma

National Cancer Institute (NCI)

Phase 3 Recruiting
600 enrolled
Lymphoid

Classic Follicular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡